2007

What does Greenpeace oppose more: Patents, or genetic modification? This question has been answered in a recent patent case where […]

India’s biotechnology industry has the potential to become a major driver of the country’s economy, but is challenged by one

I’ve been asked quite a bit recently to talk about my career path. I usually begin my talks by explaining

I previously posted how price controls and compulsory licensing give buyers more power … for a price and Abbott’s spat

In response to Thailand’s decision to issue compulsory licenses for Kaletra and for Plavix, effectively bypassing their patents by purchasing

Welcome to the April 10, 2007 edition of Carnival of Biotechnology. Finance and business development On Pharma presents a report

Following up on the success of “Building Biotechnology” (www.BuildingBiotechnology.com), I’m in the late stages of assembling a more advanced follow-up